<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01706835</url>
  </required_header>
  <id_info>
    <org_study_id>ALDOXORUBICIN-P1-PK-01</org_study_id>
    <nct_id>NCT01706835</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>An Open-Lable Phase 1 Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytRx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytRx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 open-label study to investigate the pharmacokinetics of aldoxorubicin&#xD;
      administered as a 30 minute infustion every 3 weeks for up to 8 cycles in subjects with&#xD;
      advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-Label Phase 1 Study to Investigate the Pharmacokinetics of Aldoxorubicin Administered&#xD;
      as a 30 Minute Infusion Every 3 Weeks in Subjects with Advanced Solid Tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Blood samples will be obtained for pharmacokinetics. Standard pharmacokinetic parameters, including t1/2, Cmax, AUC, Vd and CL, will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>up to 6 months</time_frame>
    <description>All subjects who receive any amount of aldoxorubicin will be included in the safety analyses, which will include the following:&#xD;
The incidence, severity, duration, causality, seriousness, and type of AEs and changes in the subject's physical examination, vital signs, and clinical laboratory results.&#xD;
Deaths and other SAEs will be tabulated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Aldoxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aldoxorubicin dosages of 230 mg/m2 or 350 mg/m2 will be given as a 30 minute infusion every 3 weeks for 8 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aldoxorubicin</intervention_name>
    <arm_group_label>Aldoxorubicin</arm_group_label>
    <other_name>INNO-206</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥18 years, male or female.&#xD;
&#xD;
          2. Histologically or cytologically confirmed malignant solid tumor that has relapsed or&#xD;
             is refractory to standard therapy.&#xD;
&#xD;
          3. Subjects who have received prior radiation therapy with stable central nervous system&#xD;
             (CNS) metastasis with no progression of brain metastasis by CT/MRI scan in last 4&#xD;
             weeks.&#xD;
&#xD;
          4. Capable of providing informed consent and complying with trial procedures.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2.&#xD;
&#xD;
          6. Life expectancy &gt;12 weeks.&#xD;
&#xD;
          7. Measurable or evaluable disease.&#xD;
&#xD;
          8. Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year,&#xD;
             surgically sterile, or practicing adequate birth control methods) for the duration of&#xD;
             the study. [Adequate contraception includes: oral contraception, implanted&#xD;
             contraception, intrauterine device implanted for at least 3 months, or barrier method&#xD;
             in conjunction with spermicide.].&#xD;
&#xD;
          9. Women of child bearing potential must have a negative serum or urine pregnancy test at&#xD;
             the Screening Visit and be non-lactating.&#xD;
&#xD;
         10. Geographic accessibility to the site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Palliative surgery, chemotherapy, immunotherapy and/or radiation treatment less than 4&#xD;
             weeks prior to the Screening Visit.&#xD;
&#xD;
          2. Exposure to any investigational agent within 30 days of the Screening Visit.&#xD;
&#xD;
          3. Laboratory values: Screening serum creatinine greater than or equal to 1.5 mg/dL,&#xD;
             alanine aminotransferase (ALT) greater than 3 times the upper limit of normal (ULN) or&#xD;
             5 times the ULN in liver metastases, total bilirubin greater than 3 times the ULN,&#xD;
             white blood cell (WBC) count &lt;3500/mm3, absolute neutrophil (ANC) count &lt; 2000/mm3,&#xD;
             platelet concentration &lt;100,000/mm3, hematocrit level &lt;25% for females or &lt;28% for&#xD;
             males (transfusion is allowed during screening).&#xD;
&#xD;
          4. Clinically evident congestive heart failure (CHF) &gt; class II of the New York Heart&#xD;
             Association (NYHA) guidelines.&#xD;
&#xD;
          5. Serious, clinically significant cardiac arrhythmias, defined as the existence of an&#xD;
             absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V.&#xD;
&#xD;
          6. Recent history (within 6 months) or current signs of active coronary artery disease&#xD;
             with or without angina pectoris.&#xD;
&#xD;
          7. Serious myocardial dysfunction defined scintigraphically (MUGA, myocardial scintigram)&#xD;
             or ultrasound determined absolute left ventricular ejection fraction (LVEF) &lt;45% of&#xD;
             predicted.&#xD;
&#xD;
          8. Known history of HIV infection.&#xD;
&#xD;
          9. Active, clinically significant serious infection requiring treatment with antibiotics,&#xD;
             antivirals or antifungals.&#xD;
&#xD;
         10. Major surgery within 4 weeks prior to treatment.&#xD;
&#xD;
         11. Substance abuse or any condition that might interfere with the subject's participation&#xD;
             in the study or in the evaluation of the study results.&#xD;
&#xD;
         12. Any condition that is unstable and could jeopardize the subject's participation in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Levitt, MD</last_name>
    <role>Study Director</role>
    <affiliation>CytRx Coorporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samuel Oschin Comprehensive Cancer Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>October 11, 2012</study_first_submitted>
  <study_first_submitted_qc>October 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2012</study_first_posted>
  <last_update_submitted>December 15, 2014</last_update_submitted>
  <last_update_submitted_qc>December 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumor</keyword>
  <keyword>aldoxorubicin</keyword>
  <keyword>phase 1</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>INNO-206</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

